We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Monosomal karyotype in MDS: explaining the poor prognosis?
- Authors
Schanz, J; Tüchler, H; Solé, F; Mallo, M; Luño, E; Cervera, J; Grau, J; Hildebrandt, B; Slovak, M L; Ohyashiki, K; Steidl, C; Fonatsch, C; Pfeilstöcker, M; Nösslinger, T; Valent, P; Giagounidis, A; Aul, C; Lübbert, M; Stauder, R; Krieger, O
- Abstract
Monosomal karyotype (MK) is associated with an adverse prognosis in patients in acute myeloid leukemia (AML). This study analyzes the prognostic impact of MK in a cohort of primary, untreated patients with myelodysplastic syndromes (MDS). A total of 431 patients were extracted from an international database. To analyze whether MK is an independent prognostic marker in MDS, cytogenetic and clinical data were explored in uni- and multivariate models regarding overall survival (OS) as well as AML-free survival. In all, 204/431 (47.3%) patients with MK were identified. Regarding OS, MK was prognostically significant in patients with 4 abnormalities only. In highly complex karyotypes (5 abnormalities), MK did not separate prognostic subgroups (median OS 4.9 months in MK+ vs 5.6 months in patients without MK, P=0.832). Based on the number of abnormalities, MK-positive karyotypes (MK+) split into different prognostic subgroups (MK+ and 2 abnormalities: OS 13.4 months, MK+ and 3 abnormalities: 8.0 months, MK+ and 4 abnormalities: 7.9 months and MK+ and 5 abnormalities: 4.9 months; P<0.01). In multivariate analyses, MK was not an independent prognostic factor. Our data support the hypothesis that a high number of complex abnormalities, associated with an instable clone, define the subgroup with the worst prognosis in MDS, independent of MK.
- Subjects
PROGNOSIS; KARYOTYPES; CHROMOSOME abnormalities; GENETICS; BONE marrow diseases
- Publication
Leukemia (08876924), 2013, Vol 27, Issue 10, p1988
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2013.187